The World Health Organization (WHO) released its first-ever guidelines for childhood and adolescent obesity. The WHO emphasizes lifestyle interventions, such as diet and exercise, over pharmacological treatments. The guidance suggests weight-loss drugs only for adolescents aged 10-19, and only after lifestyle modifications have failed. It cautions against their use in younger children.
These guidelines hold particular relevance for Novo Nordisk. The company leads the market in obesity care medications, including Wegovy and Ozempic. These drugs are a focal point of Novo Nordisk's growth strategy. The WHO's stance could shape future treatment protocols. It may also influence public perception. This could impact the long-term growth trajectory in pediatric and adolescent market segments.